Cardiac insulin-like growth factor-1 and cyclins gene expression in canine models of ischemic or overpacing cardiomyopathy

BMC Cardiovascular Disorders

Volumn 9, Issue , 2009, Pages 49-

  Mahmoudabady, Maryam ^a,b   Mathieu, Myrielle ^a   Touihri, Karim ^a   Hadad, Ielham ^a   Da Costa, Agnes M ^a   Naeije, Robert ^a   Mc Entee, Kathleen ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN B; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN E; CYCLINE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DIASTOLE; DOG; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART DILATATION; HEART HYPERTROPHY; HEART INFARCTION; HEART LEFT VENTRICLE; HEART MUSCLE; HEART VENTRICLE SEPTUM; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLE; SYSTOLIC DYSFUNCTION;

ANIMALS; ARRHYTHMIAS, CARDIAC; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; CYCLINS; DISEASE MODELS, ANIMAL; DOGS; ECHOCARDIOGRAPHY; GENE EXPRESSION REGULATION; INSULIN-LIKE GROWTH FACTOR I; MYOCARDIAL ISCHEMIA; MYOCARDIUM; POLYMERASE CHAIN REACTION; RECEPTOR, IGF TYPE 1; TRANSFORMING GROWTH FACTOR BETA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 70449512625     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-9-49     Document Type: Article

References (38)

1. Ren J, Samson WK, Sowers JR. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol 1999, 31(11):2049-2061. 10.1006/jmcc.1999.1036, 10591031.
2. Solem ML, Thomas AP. Modulation of cardiac Ca2+ channels by IGF1. Biochem Biophys Res Commun 1998, 252(1):151-155. 10.1006/bbrc.1998.9626, 9813161.
3. Lee WL, Chen JW, Ting CT, Ishiwata T, Lin SJ, Korc M, Wang PH. Insulin-like growth factor I improves cardiovascular function and suppresses apoptosis of cardiomyocytes in dilated cardiomyopathy. Endocrinology 1999, 140(10):4831-4840. 10.1210/en.140.10.4831, 10499543.
4. Anversa P, Reiss K, Kajstura J, Cheng W, Li P, Sonnenblick EH, Olivetti G. Myocardial infarction and the myocyte IGF1 autocrine system. Eur Heart J 1995, 16(Suppl N):37-45.
5. Bayes-Genis A, Conover CA, Schwartz RS. The insulin-like growth factor axis: A review of atherosclerosis and restenosis. Circ Res 2000, 86(2):125-130.
6. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004, 63(3):423-432. 10.1016/j.cardiores.2004.04.030, 15276467.
7. Hein S, Arnon E, Kostin S, Schonburg M, Elsasser A, Polyakova V, Bauer EP, Klovekorn WP, Schaper J. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003, 107(7):984-991. 10.1161/01.CIR.0000051865.66123.B7, 12600911.
8. Xiao H, Zhang YY. Understanding the role of transforming growth factor-beta signalling in the heart: overview of studies using genetic mouse models. Clin Exp Pharmacol Physiol 2008, 35(3):335-341. 10.1111/j.1440-1681.2007.04876.x, 18290874.
9. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S, Zupicich J, Alkass K, Buchholz BA, Druid H. Evidence for cardiomyocyte renewal in humans. Science 2009, 324(5923):98-102. 10.1126/science.1164680, 19342590.
10. Reiss K, Cheng W, Pierzchalski P, Kodali S, Li B, Wang S, Liu Y, Anversa P. Insulin-like growth factor-1 receptor and its ligand regulate the reentry of adult ventricular myocytes into the cell cycle. Exp Cell Res 1997, 235(1):198-209. 10.1006/excr.1997.3669, 9281369.
11. Brooks G, Poolman RA, Li JM. Arresting developments in the cardiac myocyte cell cycle: role of cyclin-dependent kinase inhibitors. Cardiovasc Res 1998, 39(2):301-311. 10.1016/S0008-6363(98)00125-4, 9798515.
12. Poolman RA, Gilchrist R, Brooks G. Cell cycle profiles and expressions of p21CIP1 AND P27KIP1 during myocyte development. Int J Cardiol 1998, 67(2):133-142. 10.1016/S0167-5273(98)00320-9, 9891946.
13. Motte S, van Beneden R, Mottet J, Rondelet B, Mathieu M, Havaux X, Lause P, Clercx C, Ketelslegers JM, Naeije R. Early activation of cardiac and renal endothelin systems in experimental heart failure. Am J Physiol Heart Circ Physiol 2003, 285(6):H2482-2491.
14. Mathieu M, Bartunek J, El Oumeiri B, Touihri K, Hadad I, Thoma P, Metens T, da Costa AM, Mahmoudabady M, Egrise D. Cell therapy with autologous bone marrow mononuclear stem cells is associated with superior cardiac recovery compared with use of nonmodified mesenchymal stem cells in a canine model of chronic myocardial infarction. J Thorac Cardiovasc Surg 2009, 138(3):646-653. 10.1016/j.jtcvs.2008.12.031, 19698851.
15. Mahmoudabady M, Mathieu M, Dewachter L, Hadad I, Ray L, Jespers P, Brimioulle S, Naeije R, McEntee K. Activin-A, transforming growth factor-beta, and myostatin signaling pathway in experimental dilated cardiomyopathy. J Card Fail 2008, 14(8):703-709. 10.1016/j.cardfail.2008.05.003, 18926443.
16. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978, 58(6):1072-1083.
17. Thomas WP, Gaber CE, Jacobs GJ, Kaplan PM, Lombard CW, Moise NS, Moses BL. Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. Echocardiography Committee of the Specialty of Cardiology, American College of Veterinary Internal Medicine. J Vet Intern Med 1993, 7(4):247-252.
18. Winer J, Jung CK, Shackel I, Williams PM. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 1999, 270(1):41-49. 10.1006/abio.1999.4085, 10328763.
19. Winer BJ. Statistical principles in experimental design. 1971, New York,: McGraw-Hill, 2.
20. Sacca L, Napoli R, Cittadini A. Growth hormone, acromegaly, and heart failure: an intricate triangulation. Clin Endocrinol (Oxf) 2003, 59(6):660-671. 10.1046/j.1365-2265.2003.01780.x, 14974906.
21. Donohue TJ, Dworkin LD, Lango MN, Fliegner K, Lango RP, Benstein JA, Slater WR, Catanese VM. Induction of myocardial insulin-like growth factor-I gene expression in left ventricular hypertrophy. Circulation 1994, 89(2):799-809.
22. Modesti PA, Vanni S, Bertolozzi I, Cecioni I, Lumachi C, Perna AM, Boddi M, Gensini GF. Different growth factor activation in the right and left ventricles in experimental volume overload. Hypertension 2004, 43(1):101-108. 10.1161/01.HYP.0000104720.76179.18, 14638623.
23. Reiss K, Kajstura J, Zhang X, Li P, Szoke E, Olivetti G, Anversa P. Acute myocardial infarction leads to upregulation of the IGF-1 autocrine system, DNA replication, and nuclear mitotic division in the remaining viable cardiac myocytes. Exp Cell Res 1994, 213(2):463-472. 10.1006/excr.1994.1224, 7914170.
24. Sun X, Ng YC. Effects of norepinephrine on expression of IGF-1/IGF-1R and SERCA2 in rat heart. Cardiovasc Res 1998, 37(1):202-209. 10.1016/S0008-6363(97)00210-1, 9539874.
25. Reiss K, Meggs LG, Li P, Olivetti G, Capasso JM, Anversa P. Upregulation of IGF1, IGF1-receptor, and late growth related genes in ventricular myocytes acutely after infarction in rats. J Cell Physiol 1994, 158(1):160-168. 10.1002/jcp.1041580120, 7505276.
26. Leri A, Kajstura J, Li B, Sonnenblick EH, Beltrami CA, Anversa P, Frishman WH. Cardiomyocyte aging is gender-dependent: the local IGF-1-IGF-1R system. Heart Dis 2000, 2(2):108-115.
27. Pecherskaya A, Rubin E, Solem M. Alterations in insulin-like growth factor-I signaling in cardiomyocytes from chronic alcohol-exposed rats. Alcohol Clin Exp Res 2002, 26(7):995-1002. 10.1111/j.1530-0277.2002.tb02633.x, 12170109.
28. Claycomb WC. Control of cardiac muscle cell division. Trends Cardiovasc Med 1992, 2:231-236.
29. Cheng W, Reiss K, Kajstura J, Kowal K, Quaini F, Anversa P. Down-regulation of the IGF-1 system parallels the attenuation in the proliferative capacity of rat ventricular myocytes during postnatal development. Lab Invest 1995, 72(6):646-655.
30. Li JM, Brooks G. Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy?. Eur Heart J 1999, 20(6):406-420. 10.1053/euhj.1998.1308, 10213344.
31. Li JM, Poolman RA, Brooks G. Role of G1 phase cyclins and cyclin-dependent kinases during cardiomyocyte hypertrophic growth in rats. Am J Physiol 1998, 275(3 Pt 2):H814-822.
32. Reiss K, Cheng W, Giordano A, De Luca A, Li B, Kajstura J, Anversa P. Myocardial Infarction Is Coupled with the Activation of Cyclins and Cyclin-Dependent Kinases in Myocytes. Exp Cell Res 1996, 225(1):44-54.
33. Qian X, Kulig E, Jin L, Lloyd RV. Expression of D-type cyclins in normal and neoplastic rat pituitary. Endocrinology 1998, 139(4):2058-2067. 10.1210/en.139.4.2058, 9528994.
34. Belso N, Szell M, Pivarcsi A, Kis K, Kormos B, Kenderessy AS, Dobozy A, Kemeny L, Bata-Csorgo Z. Differential expression of D-type cyclins in HaCaT keratinocytes and in psoriasis. J Invest Dermatol 2008, 128(3):634-642.
35. Pasumarthi KB, Nakajima H, Nakajima HO, Soonpaa MH, Field LJ. Targeted expression of cyclin D2 results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice. Circ Res 2005, 96(1):110-118. 10.1161/01.RES.0000152326.91223.4F, 15576649.
36. Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U, Schluter KD, Bohm M. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol 2002, 283(3):H1253-1262.
37. Villarreal FJ, Dillmann WH. Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta 1, fibronectin, and collagen. Am J Physiol 1992, 262(6 Pt 2):H1861-1866.
38. Sivakumar P, Gupta S, Sarkar S, Sen S. Upregulation of lysyl oxidase and MMPs during cardiac remodeling in human dilated cardiomyopathy. Mol Cell Biochem 2008, 307(1-2):159-167. 10.1007/s11010-007-9595-2, 17849172.